

AD \_\_\_\_\_

Award Number: DAMD17-02-1-0567

TITLE: Effects of Naturally-Occurring Estrogen-Fatty Acid Esters on Mammary Cell  
Growth and Carcinogenesis in Female Rats

PRINCIPAL INVESTIGATOR: Won Jun Lee, Ph.D.  
Professor B. T. Zhu  
Laura H. Mills

CONTRACTING ORGANIZATION: University of South Carolina Research Foundation  
Columbia, SC 29208

REPORT DATE: June 2005

TYPE OF REPORT: Annual Summary

20060309 154

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

*Form Approved*  
**OMB No. 0704-0188**

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

<b>1. REPORT DATE (DD-MM-YYYY)</b> 01-06-2005		<b>2. REPORT TYPE</b> Annual Summary		<b>3. DATES COVERED (From - To)</b> 1 Jun 2002 – 31 May 2005	
<b>4. TITLE AND SUBTITLE</b> Effects of Naturally-Occurring Estrogen-Fatty Acid Esters on Mammary Cell Growth and Carcinogenesis in Female Rats				<b>5a. CONTRACT NUMBER</b>	
				<b>5b. GRANT NUMBER</b> DAMD17-02-1-0567	
				<b>5c. PROGRAM ELEMENT NUMBER</b>	
<b>6. AUTHOR(S)</b> Won Jun Lee, Ph.D. Professor B. T. Zhu Laura H. Mills  E-mail: btzhu@cop.sc.edu				<b>5d. PROJECT NUMBER</b>	
				<b>5e. TASK NUMBER</b>	
				<b>5f. WORK UNIT NUMBER</b>	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b>  University of South Carolina Research Foundation Columbia, SC 29208				<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>	
				<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>	
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited					
<b>13. SUPPLEMENTARY NOTES</b>					
<b>14. ABSTRACT</b> This is the final report for the Predoctoral Taineeship Award (No. DAMD17-02-1-0567). The studies described in the original grant proposal have been completed. The major findings included the following: (i) We demonstrated, for the first time, that the naturally-occurring estrogen fatty acid esters have a differential, strong mitogenic effect in the fat-rich mammary tissues, and this effect was not observed with estradiol. (ii) We showed that the endogenous estrogen fatty acid esters are pathogenically more important than estradio with the selective induction of mammary tumor formation. (iii) We found that the estrogen esterase activity is higher in the breast tissue than in the uterus, which provides the bases for our hypothesis, the endogenous estrogen-fatty acid esters are mammary-selective estrogens for stimulation of cell growth and cancer formation.					
<b>15. SUBJECT TERMS</b> No subject terms provided.					
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>	<b>18. NUMBER OF PAGES</b>	<b>19a. NAME OF RESPONSIBLE PERSON</b>
<b>a. REPORT</b>	<b>b. ABSTRACT</b>	<b>c. THIS PAGE</b>			<b>USAMRMC</b>
U	U	U	UU	9	<b>19b. TELEPHONE NUMBER (include area code)</b>

## Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	6
Reportable Outcomes.....	6
Conclusions.....	7
References.....	8

## Introduction

This is the **final report** for the Predoctoral Traineeship Award (No. DAMD17-02-1-0567). I like to note that this Predoctoral Traineeship Award was originally awarded to Ms. Laura H. Mills in early 2002. Around June 2003, Ms. Laura Mills was approved for graduation with a PH.D. Degree. At the request of my supervisor (Professor Bao Ting Zhu), I was named as the replacement P.I. on this grant proposal shortly following Ms. Mills' departure from the project.

While serving as the replacement P.I., I helped to conduct additional studies required for the completion of this project and I have also helped with the analysis of some of the data originally obtained by Ms. Mills. Now the studies described in the original grant proposal by Ms. Laura Hook Mills have been completed.

## Body

### The Specific Aims of the Original Proposal:

- Aim 1: I will evaluate the stimulatory effects of E<sub>2</sub>-17 $\beta$ -stearate and 4-hydroxyestradiol-17 $\beta$ -stearate, two representative estrogen-fatty acid esters, on the growth of mammary vs. uterine cells in ovariectomized female Sprague-Dawley rats. Their effects will be compared with the effects of unesterified E<sub>2</sub> or 4-hydroxyestradiol. The circulating levels of prolactin, FSH, and LH will also be determined in all animals, which will serve as an indicator of estrogen's action on the pituitary. During these animal experiments, I will also collect the pituitary, thymus, and liver, and if time allows, and the growth-stimulatory effects of esterified vs. unesterified estrogens in these organs will be determined and compared with their effects in the fat-rich mammary tissue.*
- Aim 2: I will evaluate the carcinogenic activity of E<sub>2</sub>-17 $\beta$ -stearate and 4-hydroxyestradiol-17 $\beta$ -stearate on mammary vs. uterine cells in ovariectomized female Sprague-Dawley rats. The results will be compared and correlated with the growth stimulatory effects determined under Aim 1.*
- Aim 3: I will evaluate the activity of estrogen esterase (the enzyme that hydrolyzes estrogen-fatty acid esters to release bioactive estrogens) in the mammary tissue, and its activity will be compared with that found in other organs such as the uterus and liver. These analyses will provide insights into our understanding of the mechanisms underlying a preferential mitogenic action (and perhaps carcinogenic action) of estrogen-fatty acid esters in the breast over the uterus.*

**Major findings by Ms. Laura H. Mills (the original P.I.) and me (the replacement P.I.).**

1. We have completed evaluating the stimulatory effects of E<sub>2</sub>-17β-stearate on the growth of mammary vs. uterine cells in ovariectomized female Sprague-Dawley rats, and their effects were compared with the effects of unesterified E<sub>2</sub>. Experimentally, 0.5 or 5 nmol of E<sub>2</sub>-17β-stearate or E<sub>2</sub> was released daily to ovariectomized female rats through an Alzet pump implanted under the back skin of the animal for 10 or 23 days. The growth-stimulatory effect of E<sub>2</sub>-17β-stearate and E<sub>2</sub> on mammary glandular cells was determined according to 5-BrdU indices, and their effect on the uterus was determined by measuring both the 5-BrdU-labeling index and the uterine wet weight. We found that chronic treatment of ovariectomized female rats with 0.5 or 5 nmol/day of E<sub>2</sub>-17β-stearate for 10 or 23 days had a stronger stimulatory effect on mammary glandular cell proliferation than treatment with equimolar doses of E<sub>2</sub>. In the uterus, however, E<sub>2</sub> was more active in stimulating the proliferation of uterine endometrial cells than E<sub>2</sub>-17β-stearate at equimolar doses. Our results demonstrated, for the first time, that a naturally-occurring E<sub>2</sub>-17β-fatty acid ester has a differential, strong mitogenic effect in the fat-rich mammary tissues, and this effect was not observed with E<sub>2</sub>.

2. We have also determined the plasma levels of prolactin (PRL), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) in ovariectomized female rats treated with E<sub>2</sub>-17β-stearate or E<sub>2</sub>. We found that chronic administration of E<sub>2</sub> showed a stronger negative regulatory effect on the plasma LH levels than E<sub>2</sub>-17β-stearate. The plasma levels of FSH in ovariectomized female rats were not significantly affected by treatment with E<sub>2</sub>-17β-stearate or E<sub>2</sub>. Chronic administration of E<sub>2</sub>-17β-stearate or E<sub>2</sub> markedly increased the plasma PRL levels, but their effects were not significantly different from each other.

3. We have also evaluated the activity of the estrogen-fatty acid ester with E<sub>2</sub> for the induction of mammary vs. pituitary tumors in intact female ACI rats. Experimentally, the animals received an s.c. implantation of a 20 mg pellet (containing 18 μmol of an estrogen plus cholesterol or 100% cholesterol as the control) at 62 ± 3 days of their age, and the animals were monitored for a total period of 8 months. Among the 25 control animals, none developed mammary tumor and all lived healthily during the whole carcinogenesis experiment. Among the 26 animals receiving an E<sub>2</sub> pellet, all the animals developed a large pituitary tumor (average weight = 254 ± 83 mg), but only 8 of them developed mammary tumor(s). A majority of the animals died or had to be terminated early because of severe sickness, likely due to the presence of the large pituitary tumor. Among the 26 animals implanted with the same molar dose of an E<sub>2</sub>-fatty acid ester preparation (containing 63% E<sub>2</sub>-17β-stearate and 37% E<sub>2</sub>-17β-palmitate), a total of 9 animals developed mammary tumor, and none of the animals died of non-breast cancer-related sickness. Only 3 animals (11.5%; all with mammary tumor) developed a pituitary tumor, with a slightly smaller average size (173 ± 75 mg). In conclusion, while E<sub>2</sub> was far stronger in stimulating the formation of pituitary tumor (100% incidence) than mammary tumor (30.7% incidence), E<sub>2</sub>-fatty acid esters had a somewhat stronger activity than E<sub>2</sub> in inducing the mammary tumor but only had very weak activity in inducing pituitary tumor. Our data suggest that the endogenous E<sub>2</sub>-fatty acid esters are pathogenically more important than E<sub>2</sub> for the *selective* induction of mammary tumor formation.

4. We have evaluated the activity of estrogen esterase (the enzyme that hydrolyzes estrogen-fatty acid esters to release bioactive estrogens) in the mammary tissue. We found that this esterase activity is higher in the breast tissue than in the uterus. This is a very interesting novel finding, which provided the basis for our hypothesis the endogenous estrogen-fatty acid esters are mammary-selective estrogens for the induction of cell growth and cancer formation.

### Key Research Accomplishments

1. We demonstrated, for the first time, that a naturally-occurring estrogen fatty acid ester has a differential, strong mitogenic effect in the fat-rich mammary tissues, and this effect was not observed with E<sub>2</sub>.
2. We showed that the endogenous estrogen fatty acid esters are pathogenically more important than E<sub>2</sub> for the *selective* induction of mammary tumor formation.
3. We found that the estrogen esterase activity is higher in the breast tissue than in the uterus, which provides the basis for our hypothesis the endogenous estrogen-fatty acid esters are mammary-selective estrogens for stimulating cell growth and cancer formation.

### Reportable Outcomes

Listed below are papers and abstracts that have come out of this award, with the P.I.'s names highlighted.

**Mills LH**, Lee AJ and Parlow AF and Zhu BT [2001] Preferential growth stimulation of mammary glands over uterine endometrium in female rats by a naturally occurring estradiol-17 $\beta$ -fatty acid ester. *Cancer Research* 61: 5764-5770.

Lee AJ, **Mills LH**, Kosh JW, Conney AH and Zhu BT [2002] NADPH-dependent metabolism of estrone by human liver microsomes. *Journal of Pharmacology and Experimental Therapeutics* 300: 838-849.

**Hook LL** (maiden name for **Laura H. Mills**), Lee AJY and Zhu BT [2000] Differential stimulatory actions of estradiol-17 $\beta$ -stearate on the growth of rat mammary vs. uterine cells. *Proceedings of the American Association for Cancer Research* 41: 429, San Francisco.

**Mills LH** and Zhu BT [2001] Chronic administration of 17 $\beta$ -estradiol inhibits intramammary lymphocyte proliferation in female rats. *Proceedings of the American Association for Cancer Research* 42: 237, New Orleans, Louisiana.

**Mills LH**, Sowell JW, Chapman JM and Zhu BT [2002] Synthesis of 4-hydroxyestradiol-17 $\beta$ -stearate, an estrogen fatty acid ester, and its stable prodrug 4-hydroxyestradiol-3,4-diacetate 17 $\beta$ -stearate. The South Eastern Regional Meeting of the American Chemical Society (SERMACS), November 13-16, 2002, Charleston, South Carolina.

**Mills LH, Lee WJ and Zhu BT [2003]** Naturally-occurring estradiol-17 $\beta$ -fatty acid ester, but not estradiol-17 $\beta$ , preferentially induces the development of mammary tumor in female ACI rats. Proceedings of the American Association for Cancer Research 44: 835-836.

**Mills LH, Lee WJ and Zhu BT [2003]** Naturally-occurring estradiol-17 $\beta$ -fatty acid ester, but not estradiol-17 $\beta$ , preferentially induces the development of mammary tumor in female ACI rats. **Manuscript in preparation (to be submitted to Cancer Research).**

**Listed below are some other papers published by the replacement P.I. during his graduate studies under the supervision of Dr. B. T. Zhu:**

**Liu ZJ, Lee WJ and Zhu BT [2005]** Selective insensitivity of ZR-75-1 human breast cancer cells to 2-methoxyestradiol: Evidence for Type II 17 $\beta$ -hydroxysteroid dehydrogenase as the underlying cause. Cancer Research 65: 5802-5811.

**Lee WJ and Zhu BT [2005]** Modulation of DNA methylation by catechol-O-methyltransferase. Medical Hypotheses and Research 2: 325-337.

**Lee WJ and Zhu BT [2005]** Inhibition of enzymatic DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols. Carcinogenesis [August 4, 2005; Epub ahead of print] [in press].

**Lee WJ, Shim JY and Zhu BT [2005]** Mechanisms for inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Molecular Pharmacology [July 21, 2005; Epub ahead of print] [in press].

**Lee WJ and Zhu BT [2004]** Strong inhibition of DNA methylation by caffeic acid and chlorogenic acid, two polyphenolic components present in coffee. Proceedings of the American Association for Cancer Research 45, Orlando, Florida.

**Lee WJ and Zhu BT [2005]** Modulation of DNA methylation by catechol-O-methyltransferase. Proceedings of the American Association for Cancer Research 46: abstract 2749. Anaheim, California. April 16-20, 2005.

**Lee WJ and Zhu BT [2005]** Modulation of the rate of enzymatic DNA methylation by catechol-O-methyltransferase. South Carolina Alliance for Cancer Chemoprevention, 3<sup>rd</sup> Annual Symposium, abstract 20, May 17-18, 2005.

## **Conclusions**

**The naturally-occurring estrogen fatty acid esters have a preferential mitogenic effect in the fat-rich mammary tissues compared to estradiol. Also, these endogenous estrogen fatty acid esters are pathogenically more important than estradiol for the induction of mammary tumor formation in the animal model.**

## References

**Mills LH**, Lee AJ and Parlow AF and Zhu BT [2001] Preferential growth stimulation of mammary glands over uterine endometrium in female rats by a naturally occurring estradiol-17 $\beta$ -fatty acid ester. *Cancer Research* 61: 5764-5770.

Lee AJ, **Mills LH**, Kosh JW, Conney AH and Zhu BT [2002] NADPH-dependent metabolism of estrone by human liver microsomes. *Journal of Pharmacology and Experimental Therapeutics* 300: 838-849.

**Hook LL** (Ms. **Laura H. Mills's** maiden name), Lee AJY and Zhu BT [2000] Differential stimulatory actions of estradiol-17 $\beta$ -stearate on the growth of rat mammary vs. uterine cells. *Proceedings of the American Association for Cancer Research* 41: 429, San Francisco.

**Mills LH** and Zhu BT [2001] Chronic administration of 17 $\beta$ -estradiol inhibits intramammary lymphocyte proliferation in female rats. *Proceedings of the American Association for Cancer Research* 42: 237, New Orleans, Louisiana.

**Mills LH**, Sowell JW, Chapman JM and Zhu BT [2002] Synthesis of 4-hydroxyestradiol-17 $\beta$ -stearate, an estrogen fatty acid ester, and its stable prodrug 4-hydroxyestradiol-3,4-diacetate 17 $\beta$ -stearate. The South Eastern Regional Meeting of the American Chemical Society (SERMACS), November 13-16, 2002, Charleston, South Carolina.

**Mills LH**, **Lee WJ** and Zhu BT [2003] Naturally-occurring estradiol-17 $\beta$ -fatty acid ester, but not estradiol-17 $\beta$ , preferentially induces the development of mammary tumor in female ACI rats. *Proceedings of the American Association for Cancer Research* 44: 835-836.

Liu ZJ, **Lee WJ** and Zhu BT [2005] Selective insensitivity of ZR-75-1 human breast cancer cells to 2-methoxyestradiol: Evidence for Type II 17 $\beta$ -hydroxysteroid dehydrogenase as the underlying cause. *Cancer Research* 65: 5802-5811.

**Lee WJ** and Zhu BT [2005] Modulation of DNA methylation by catechol-O-methyltransferase. *Medical Hypotheses and Research* 2: 325-337.

**Lee WJ** and Zhu BT [2005] Inhibition of enzymatic DNA methylation by caffeic acid and chlorogenic acid, two common catechol-containing coffee polyphenols. *Carcinogenesis* [August 4, 2005; Epub ahead of print] [in press].

**Lee WJ**, Shim JY and Zhu BT [2005] Mechanisms for inhibition of DNA methyltransferases by tea catechins and bioflavonoids. *Molecular Pharmacology* [July 21, 2005; Epub ahead of print] [in press].

**Lee WJ** and Zhu BT [2004] Strong inhibition of DNA methylation by caffeic acid and chlorogenic acid, two polyphenolic components present in coffee. *Proceedings of the American Association for Cancer Research* 45, Orlando, Florida.



**Lee WJ and Zhu BT [2005]** Modulation of DNA methylation by catechol-O-methyltransferase. Proceedings of the American Association for Cancer Research 46: abstract 2749. Anaheim, California. April 16-20, 2005.

**Lee WJ and Zhu BT [2005]** Modulation of the rate of enzymatic DNA methylation by catechol-O-methyltransferase. South Carolina Alliance for Cancer Chemoprevention, 3<sup>rd</sup> Annual Symposium, abstract 20, May 17-18, 2005.

## **Appendices**

Not included.